Logynon

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Logynon

What is Logynon?

Property Description
Active Ingredients Ethinylestradiol, Levonorgestrel
Form Oral Coated Tablet (Tri-phasic)
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Pregnancy Prevention (Contraception)
Origin Synthetic Hormones

Logynon is a prescription-only pharmaceutical preparation officially classified as a combined hormonal contraceptive (CHC), whose primary purpose is pregnancy prevention for women of reproductive potential. This categorization places Logynon within the high-level pharmacological group of Sex hormones and modulators of the genital system (ATC Code G03AA07), defining it as an oral medication that uses synthetic hormone components to achieve reliable contraception. Combined oral contraceptives like Logynon are highly effective methods for birth control when used correctly.


Composition and Tri-Phasic Form

Logynon is a combination product that contains two synthetic active ingredients: the estrogen compound Ethinylestradiol and the progestin compound Levonorgestrel. These synthetic compounds are derivatives of natural sex hormones engineered for reliable oral activity. The chemical identity of the progestin, Levonorgestrel, is established.

The medicine is formulated for oral administration as a coated tablet and is uniquely structured as a tri-phasic regimen. This means the concentrations of both Levonorgestrel and Ethinylestradiol change three times across the cycle of active tablets, distinguishing it from constant-dose (monophasic) pills. This tri-phasic dosing is designed to closely mimic the body's natural hormonal cycle while maintaining continuous contraceptive efficacy.

What side effects are possible with Logynon?

Possible Side Effects and Safety Information

Serious and Clinically Significant Adverse Reactions

The most serious documented risk associated with combined hormonal contraceptives, including Logynon (a levonorgestrel-containing pill), is an increased risk of Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE). These are rare but can be life-threatening events such as deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (heart attack), and stroke. The risk of VTE is generally highest during the first year of use and upon re-starting the medication after a break of four or more weeks.

Other serious reactions include an increased risk of certain cancers (e.g., breast cancer, though a causal link is not established) and the occurrence of liver tumors (benign or malignant).

Common and Uncommon Adverse Reactions

Adverse reactions classified as common (1/100 users) include headache, depressed mood, mood changes, breast pain/tenderness, nausea, abdominal pain, and weight increase.

Uncommon reactions (1/1000 users) include decreased libido, migraine, vomiting, diarrhea, fluid retention, skin rash, and urticaria.

Safety-Related Restrictions and Contraindications

Logynon is contraindicated in women with pre-existing conditions that significantly increase the risk of thrombosis. These include a history of DVT/PE, cerebrovascular disease, uncontrolled hypertension, diabetes with vascular damage, or known hypercoagulopathies. It is also contraindicated in women with known or suspected breast cancer, liver tumors, severe hepatic impairment, or undiagnosed abnormal genital bleeding.

Special caution is required and the product must be temporarily discontinued at least four weeks before any major surgery, especially those involving the legs or pelvis, or during periods of prolonged immobilization. Monitoring of blood pressure and glucose is required for women with pre-existing hypertension or diabetes, respectively.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for combined hormonal contraceptives containing Ethinylestradiol and Levonorgestrel, such as Logynon, provide specific information regarding overdosage, which is categorized based on expected clinical signs and mandated emergency actions.

Documented Overdose Manifestations

Acute ingestion of large doses is generally considered not likely to be life-threatening, and no serious undesirable effects have been reported by regulators. The documented clinical manifestations of overdose primarily include nausea and vomiting. Withdrawal bleeding may also occur in females; notably, this specific manifestation is documented to occur in prepubertal girls following accidental ingestion.

Overdose Profile Regulatory Statement
Severity Classification Not likely to be life-threatening
Antidote Status No specific antidote is known

Required Emergency Actions

Despite the low acute toxicity classification, regulatory guidance mandates specific emergency actions. In cases of suspected overdose, individuals must seek medical help right away and call poison control or local emergency services. Because there is no specific antidote available, the treatment following overdose is exclusively symptomatic and supportive. Further management is officially directed to the symptoms present, and procedures such as the administration of activated charcoal may be considered in extreme cases as a supportive measure.

Therapeutic Uses of Logynon

What Logynon Treats: Main Uses and Benefits

Logynon's therapeutic scope is commonly used in contexts marked by increased discomfort or tension and supports across domains where symptomatic support is needed. Its primary use is effective pregnancy prevention. Logynon is applied in addressing this health situation for women of reproductive age, and may assist with managing symptoms.

Core Therapeutic Focus

Logynon is applied in addressing pregnancy prevention. It may assist with cycle predictability by contributing to more regular cycle patterns. This provides support that helps ease the overall symptom burden related to fertility and supports general well-being during symptomatic phases. The medication is relevant for easing pregnancy prevention, assists with cycle predictability, and is commonly used to help with symptom clusters that may become intense or disruptive.

Supportive Symptom Management

The medication is commonly used to help with symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort and flow. Furthermore, it is considered relevant in conditions characterized by periods of heightened symptoms, such as hormone-related acne. This assists with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Pain and Flow The medication plays a role in managing symptoms related to physical discomfort and flow, and provides supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Logynon

Eligibility Scope Official Regulatory Classification
Populations for whom use is allowed Females of reproductive potential (post-menarcheal) [Source 1.2, 1.7].
Populations for whom use is not recommended Breastfeeding/Lactating Females [Source 1.1, 1.7].
Pregnancy Eligibility Status Contraindicated (known or suspected pregnancy) [Source 1.2, 1.7].

Contraindicated Populations and Conditions

Use of Logynon is absolutely contraindicated for several high-risk populations, based strictly on regulatory labeling [Source 1.2, 1.7].

Contraindications Include:

  • Thrombotic Risk: Presence or history of Venous or Arterial Thromboembolism (VTE/ATE), including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, or a hereditary predisposition to clotting [Source 1.2, 1.7].
  • Vascular/Metabolic: Women who smoke and are over 35 years old; severe diabetes mellitus with vascular symptoms; severe hypertension; or migraine with aura [Source 1.2, 2.6].
  • Malignancy/Hepatic: Known or suspected sex-steroid influenced malignancies (e.g., breast cancer) and severe hepatic disease, liver tumours, or active Hepatitis C drug use (ombitasvir/paritaprevir/ritonavir combinations) [Source 1.2, 1.4].

Age and Special Population Rules

Logynon is indicated only after menarche and is not applicable or indicated after menopause [Source 1.6, 1.7]. Use is restricted around major surgery involving prolonged immobilisation and must be postponed to 21 to 28 days after delivery for non-breastfeeding females [Source 1.2, 1.4].

What should I know about interactions with other medicines?

Logynon, a combined oral contraceptive containing ethinylestradiol and levonorgestrel, has established interactions with several types of medicines and products. These interactions can potentially reduce the contraceptive's effectiveness or alter the concentration of co-administered drugs.

Impact on Contraceptive Efficacy

Enzyme-Inducing Medicines are the primary cause of reduced effectiveness. These medicines speed up the breakdown of the contraceptive hormones in the body, which can lead to breakthrough bleeding and possible contraceptive failure. This category includes certain medicines used to treat epilepsy (e.g., phenytoin, carbamazepine, primidone), some antibiotics (e.g., rifampicin, griseofulvin), and the herbal remedy St John's wort (Hypericum perforatum). Patients using these for short-term therapy must use a non-hormonal barrier method during and for 28 days after stopping the interacting drug. Women on long-term enzyme-inducing therapy are generally advised to use an alternative contraceptive method.

Conversely, strong and moderate CYP3A4 inhibitors (such as certain antifungal and macrolide antibiotics) may increase the plasma levels of the contraceptive hormones.

Effects on Other Medicines

Logynon may affect the metabolism of certain other medicines, leading to changes in their concentration. For example, it may increase the concentration of drugs like cyclosporin and tizanidine or decrease the concentration of drugs such as lamotrigine.

Contraindicated Combinations

Logynon is strictly contraindicated for use with certain medicine combinations intended to treat Hepatitis C (specifically those containing ombitasvir/paritaprevir/ritonavir plus dasabuvir, or glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir/voxilaprevir) due to the risk of liver enzyme elevations.

Mechanism of Action

Logynon is a combined hormonal formulation containing the synthetic progestogen levonorgestrel and the synthetic estrogen ethinylestradiol. Its mechanism involves a coordinated action on the hypothalamic-pituitary-ovarian (HPO) axis and peripheral tissues.

The progestogen component, levonorgestrel, acts as a primary modulator by binding to the progesterone receptors. This binding suppresses the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, leading to the inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary gland. The resulting dampened gonadotropin levels prevent the development of a dominant ovarian follicle and inhibit the mid-cycle LH surge, thereby preventing the process of ovulation (egg release).

Simultaneously, levonorgestrel alters the consistency of the cervical mucus, significantly increasing its viscosity to create a physical barrier that impedes sperm migration into the upper reproductive tract. Both active components also induce changes in the endometrium (uterine lining), causing glandular atrophy and stromal pseudodecidualization, which modifies the environment of the uterus. This three-pronged hormonal cascade—central suppression of the HPO axis, modulation of cervical fluid, and endometrial alteration—collectively determines the physiological consequence of the formulation.

Dosage and Administration Information

How to Use Logynon

Logynon is a combined hormonal contraceptive intended for oral use and administered on a cyclic 28-day schedule. The medication is available as a coated tablet and is prescribed as a tri-phasic regimen, which means the concentrations of the two active ingredients, ethinylestradiol and levonorgestrel, change three times across the 21 active tablets.

The Standard Cyclic Administration

The general principle of administration involves taking one tablet daily for 28 consecutive days, or following a 21-day active regimen followed by a tablet-free interval. Specifically, patients take one active tablet daily for 21 consecutive days. This is followed by a 7-day tablet-free interval, during which the next pack is not started. The subsequent 21-day active cycle commences immediately after this 7-day interval is complete.

Key Procedural Requirements

Due to the varying hormone levels, tablets must be taken in the exact order directed on the blister packaging to ensure correct dose progression. It is crucial to take the tablet at approximately the same time every day to maintain the necessary schedule. The intake of Logynon is not dependent on meals and can be taken with or without food, though it may be taken with some liquid.

Specialized instructions govern the procedure for a missed tablet, with specific steps depending on the duration of the delay (less than or greater than 12 hours) and the week of the cycle. Furthermore, for those initiating use after specific clinical events, such as childbirth, the first cycle should generally begin on days 21 to 28 following delivery.

Recent Clinical Evidence

Logynon: Recent Clinical Evidence

The formulation of Logynon—which contains the combined hormones levonorgestrel and ethinylestradiol—is a well-established type of oral contraceptive. Recent clinical research and large-scale observational studies continue to focus on its long-term safety profile and comparative outcomes, particularly against newer hormonal methods.


Efficacy and Contraceptive Reliability

Logynon is highly effective for pregnancy prevention when taken correctly. Observational data typically place its effectiveness at over 99% with perfect use in controlled settings. However, typical use, which accounts for missed doses or other factors, is often associated with a lower rate of reliability, consistent with other combined oral contraceptives.

Safety Profile and Risk Associations

Clinical evidence consistently confirms an increased risk of venous thromboembolism (VTE) compared to women who are not using combined hormonal contraception. The risk level is generally comparable to other combined pills containing levonorgestrel.

Health Outcome Study Finding Comparison
VTE Risk Small but measurable increase (VTE) Lower than the VTE risk during pregnancy
Cancer Risk Slight, temporary increase in breast/cervical cancer risk observed during use Risk reduces to baseline after discontinuation (typically 10 years)
Bleeding Patterns Older comparative studies noted favorable bleeding control and less spotting compared to some monophasic pills. Outcomes may vary depending on the specific product comparison.

Non-Contraceptive Benefits

Studies suggest combined oral contraceptives may be associated with secondary benefits, including a reduction in menstrual pain and lighter, more predictable periods. Research also indicates a potential reduced incidence of conditions such as ovarian and endometrial cancers, which is common to the class of combined oral pills.

Key Studies & References Systematic Review of Combined Oral Contraceptives and Venous Thromboembolism

Frequently Asked Questions (FAQ)

Common questions about Logynon (FAQ)


Q: How quickly does Logynon start working to prevent pregnancy?

Official product information describes that 7 days of uninterrupted active tablet-taking are generally required to achieve the necessary hormonal suppression of the body's natural hormone signals (the hypothalamic-pituitary-ovarian axis). This initial period is critical for ensuring reliable contraceptive efficacy when initiating the pill.


Q: What happens if I miss a pill while taking Logynon?

Regulatory documents outline different procedures based on the timing of the missed tablet. If the user is less than 12 hours late in taking an active tablet, contraceptive protection is generally maintained. If the delay is more than 12 hours, contraceptive protection may be reduced, and specific steps are defined based on the week of the cycle.


Q: Can Logynon interact with common pain relievers like ibuprofen?

Official regulatory documents list specific interacting agents that may reduce Logynon's effectiveness, such as certain enzyme-inducing drugs and some antibiotics. Common pain relievers like ibuprofen are typically not cited in official documents as being enzyme-inducers that decrease contraceptive efficacy.


Q: Are there any long-term health risks associated with taking Logynon for many years?

Official documentation indicates that combined hormonal contraceptives are associated with an increased risk of venous thromboembolism (VTE) compared to non-users. Additionally, studies have observed a slight, temporary increase in the risk of certain cancers during use, with the risk generally returning to baseline after the medication is discontinued.


Q: How soon after stopping Logynon can a person become pregnant?

Official product information notes that fertility is expected to return after stopping the pill, and no known permanent impact on fertility is indicated. However, official documents do not uniformly define the specific time it takes for ovulation to resume, as this process can vary for each individual.


Q: Why is Logynon considered a combined oral contraceptive?

Logynon is officially described as a combined oral contraceptive because it contains a combination of two synthetic hormone types: an oestrogen (ethinylestradiol) and a progestogen (levonorgestrel). These components work together to inhibit ovulation, thicken cervical mucus, and modify the uterine lining.


Q: Is Logynon the same kind of pill as other combination pills?

Regulatory information defines Logynon as a tri-phasic regimen. This means that the hormone levels change three times across the cycle of active tablets, which distinguishes it structurally from constant-dose, or monophasic, combined oral contraceptives.


Q: Does Logynon cause weight gain for most people?

Official regulatory documents classify weight increase as a Common Adverse Reaction. This indicates it is among the effects reported by 1 in 100 people or more who use the medication.


Q: Are headaches a common side effect of Logynon?

Yes, official regulatory documents list headache as a Common Adverse Reaction. This is a frequently reported effect, meaning it may affect 1 in 100 people or more who use the medication.


Q: Does Logynon affect mood or cause anxiety?

Official product information classifies depressed mood and general mood changes as Common Adverse Reactions. This indicates they are among the frequently reported experiences by users of the medication.


Q: Will Logynon make my period lighter or shorter?

Studies suggest that combined oral contraceptives are associated with secondary non-contraceptive benefits, including a reduction in menstrual pain and the reported tendency for lighter, more predictable periods.


Q: Can Logynon be used to help with acne?

Due to the components of Logynon, this type of oral contraceptive is recognized as having potential non-contraceptive benefits, including effects that may help with symptoms like acne.


Q: Is it normal to have spotting or breakthrough bleeding when starting Logynon?

Official documents note that bleeding and spotting between periods can sometimes occur during the first few months of use. This is often considered a temporary adjustment period as the body gets used to the hormonal changes.


Q: How long does spotting usually last after starting Logynon?

Irregular bleeding or spotting when starting the pill is typically noted to stop once the body has adjusted, which often happens within the first few months of treatment. Persistent bleeding that continues or becomes heavy warrants an evaluation.


Q: Do I need to use a backup method of contraception when first starting Logynon?

If Logynon is initiated on days 2 to 5 of a menstrual cycle, official instructions recommend using a non-hormonal barrier method in addition for the first 14 days of tablet-taking.


Q: Does Logynon impact fertility after stopping the pill?

Official information regarding pregnancy and lactation notes that the return of fertility is expected after discontinuing the pill. This indicates that there is no known permanent negative impact on fertility associated with its use.


Q: Why are there 7 inactive/dummy pills in a Logynon pack?

The inactive (placebo) tablets are included to help maintain a daily routine of tablet-taking. Their primary function is to ensure that the 7-day hormone-free interval is not accidentally extended, which is a critical safety measure for maintaining consistent contraceptive efficacy.


Q: Does Logynon have a known effect on breast size?

Official adverse reaction lists indicate that breast pain/tenderness is a common side effect of the medication. Additionally, breast enlargement is listed as an uncommon adverse reaction.


Q: Can using Logynon affect cholesterol levels?

Official product information indicates that the use of oral contraceptives may influence the results of certain laboratory tests. This includes the plasma levels of lipid and lipoprotein fractions (e.g., cholesterol), so laboratory staff should be informed if the patient is using an oral contraceptive.


Q: Is it necessary to take Logynon at the exact same time every day?

Official instructions state that it is important to take the tablet at approximately the same time every day. Protection is maintained if the tablet is taken less than 12 hours late, but the risk of reduced efficacy increases beyond that time.


Q: Does alcohol consumption interfere with Logynon's effectiveness?

Alcohol is generally not listed as a substance that reduces the efficacy of the contraceptive hormones via direct metabolic interaction. However, if alcohol consumption leads to vomiting or severe diarrhoea within 4 hours of taking the pill, absorption may be incomplete, and efficacy could be reduced.


Q: What is the difference between Logynon and Logynon ED?

The official product information for the ED designation (meaning Every Day) indicates that these packs contain 28 tablets in total, which includes 7 inactive/placebo tablets. This differs from the standard 21-day pack, which requires a separate 7-day pill-free break.


Q: Can Logynon be used by women who have not had children?

Official regulatory documents indicate that Logynon is intended for use in females of reproductive potential (post-menarcheal). There is no restriction on its use based on parity (whether or not a woman has previously had children).


Q: Does Logynon affect results of any common medical tests?

Yes, official product information states that combined oral contraceptives may influence the results of certain laboratory tests. This includes biochemical parameters of the liver, thyroid, adrenal, and renal function, as well as the plasma levels of carrier proteins.


Q: How does the triphasic nature of Logynon relate to the menstrual cycle?

The triphasic structure involves the hormone levels changing three times over the course of the active tablets. This dosing regimen is designed to mimic the body's natural hormone levels during a menstrual cycle while maintaining reliable contraceptive efficacy.


Q: Is it normal to feel nauseous when starting Logynon?

Yes, regulatory documents list nausea as a Common Adverse Reaction. This means it is an effect reported by many users, and it is frequently experienced, particularly when first starting the medication.


Q: What should I do if I vomit or have severe diarrhea after taking Logynon?

Official instructions state that if vomiting or severe diarrhoea occurs within 4 hours of taking a tablet, the efficacy of the contraceptive may be reduced due to incomplete absorption. In this situation, the continued use of the pack should be supplemented with additional non-hormonal methods for 7 days.


Q: Are there any known interactions between Logynon and antibiotics?

Official documents specify that certain antibiotics are known as enzyme-inducing medicines that can reduce contraceptive effectiveness. Specifically, the antibiotics rifampicin and griseofulvin are listed as known interacting agents in this category.


Q: Why is smoking a concern when taking Logynon?

Official information states that the combination of smoking and using Logynon is contraindicated, particularly for women over 35, due to a significantly increased risk of serious cardiovascular adverse reactions. These risks include arterial thromboembolism (ATE), which can lead to events like stroke and heart attack.


Q: Can taking Logynon cause changes in vision?

Official patient information states that certain vision changes, such as sudden loss of vision or blurred vision, are listed as potential signs of a serious side effect (blood clot). These changes warrant a prompt evaluation.

How should Logynon be stored and disposed of?

How to Store and Dispose of Logynon

Logynon must be stored according to regulatory requirements to ensure its stability. Tablets should be stored below 25 C and must be protected from moisture. To maintain quality, the medication must be kept in its original container and should not be used past the expiration date printed on the packaging.

Official Handling and Safety

It is mandatory to keep Logynon out of the sight and reach of children.

Disposal Instructions

Unused or expired Logynon must not be disposed of via wastewater or regular household waste. Disposal should follow local requirements for pharmaceutical waste. Patients should consult a pharmacist for guidance on medicine take-back programs or appropriate discard procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Logynon found in:

A-Z Index: